drugset / Trial / NCT05205837

A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial

NCT05205837

Phase 4 Terminated 8 enrolled Rigshospitalet, Denmark
RandomizedParallel-groupDouble-blindTreatment

Summary

The overall objective of this randomized trial is to investigate the effects of treatment of AAS- induced male hypogonadism with combined therapy of letrozole and hCG compared with placebo on reproductive hormone levels, adherence to cessation of AAS use, fertility, cardiac function and quality of life.

Timeline

Start
2021-11-24
Primary completion
2023-08-15
Completion
2023-08-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Letrozole Other / unclassified 2.5 mg Intramuscular
Comparator hCG Unknown 1500 iu Intramuscular